Novartis board faces investor scrutiny after M&A misfires and R&D setbacks on September 13, 2026 Artisan Partners Avidity Biosciences Clinical Trials del-desiran Giovanni Caforio investor scrutiny M&A strategy Novartis Pelacarsen +